過活動膀胱(OAB)治療の世界市場予測(~2022年):抗コリン・ソリフェナシン、オキシブチニン、フェソテロジン、ダリフェナシン、ミラベグロン、ボトックス、神経刺激

◆英語タイトル:Overactive Bladder Treatment Market by Pharmacotherapy (Anticholinergic- Solifenacin, Oxybutynin, Fesoterodine, Darifenacin; Mirabegron; BOTOX; Neurostimulation), Disease Type (Idiopathic and Neurogenic Bladder Overactivity) - Global Forecast to 2022
◆商品コード:MAM-PH5449
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2017年7月27日
◆ページ数:244
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、過活動膀胱(OAB)治療の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、薬物療法タイプ別分析、疾患タイプ別分析、地域別分析、過活動膀胱(OAB)治療の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

・イントロダクション
・エグゼクティブサマリー
・過活動膀胱(OAB)治療の世界市場:市場インサイト
・過活動膀胱(OAB)治療の世界市場:市場概観/市場動向
・過活動膀胱(OAB)治療の世界市場:市場シェア分析
・過活動膀胱(OAB)治療の世界市場:薬物療法タイプ別分析/市場規模
・過活動膀胱(OAB)治療の世界市場:疾患タイプ別分析/市場規模
・過活動膀胱(OAB)治療の世界市場:地域別分析/市場規模
・過活動膀胱(OAB)治療のアジア市場規模予測
・過活動膀胱(OAB)治療のヨーロッパ市場規模予測
・過活動膀胱(OAB)治療のアメリカ市場規模予測
・過活動膀胱(OAB)治療の世界市場動向
・過活動膀胱(OAB)治療の世界市場:競争状況
・過活動膀胱(OAB)治療の世界市場:関連企業分析
...

※上記の和訳は最新内容ではない場合があります。
【レポートの概要】

“Global overactive bladder treatment market is projected to grow at a CAGR of 2.9%.”The global overactive bladder treatment market is estimated to grow at a CAGR of 2.9% from 2017 to 2022, to reach USD 4.19 billion by 2022. The key factors driving the growth of this market include the rising prevalence of overactive bladder (OAB) coupled with the growing geriatric population and rising neurological disorders, namely, Parkinson’s Disease (PD), stroke, and multiple sclerosis (MS). However, the undesired systemic effects of current OAB treatments may hinder the growth of the market to a certain extent during the forecast period.

“The neurostimulation and BOTOX treatment segments are expected to grow at the highest CAGR.”
On the basis of pharmacotherapy, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, and neurostimulation. The neurostimulation and BOTOX treatment segments are expected to witness the highest growth during the forecast period. The growth of these segments is mainly due to the higher efficacy and longevity of the treatment effects as compared to anticholinergics.

“The solifenacin to dominate the global overactive bladder treatment market during the forecast period.”
Based on anticholinergic drugs, the overactive bladder treatment market is further classified into darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium, and other anticholinergics (imidafenacin, emepronium, flavoxate, meladrazine, terodiline, propiverine, and desfesoterodine). Solifenacin is expected to command for the largest share of the global overactive bladder treatment market owing to its efficacy as compared to other drugs of its class.

“RoAPAC to witness the highest growth during the forecast period (2017-2022)”
The U.S. held the largest share of the global overactive bladder treatment market in 2016, while the Rest of Asia-Pacific (RoAPAC) is expected to witness the highest growth during 2017 to 2022. Growing healthcare expenditure in countries like India, China, and Singapore; favorable demographics; and aggressive marketing by pharma companies leading to rising awareness on OAB are the key factors responsible for the growth of this market in the RoAPAC region.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–60%, Tier 2–25% and Tier 3–15%
• By Designation – C-level–17%, Director Level–45%, Others–38%
• By Region – North America–42%, Europe–28%, Asia-Pacific–17%, RoW–13%

Some of the major market players in the overactive bladder treatment market are Astellas Pharma, Inc. (Japan), Pfizer, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (U.S.), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France), Aurobindo Pharma Limited (India), Apotex, Inc. (Canada), and Cogentix Medical, Inc. (U.S.).

Research Coverage:
The report analyzes the overactive bladder treatment market and aims at estimating the market size and future growth potential of this market based on various segments such as pharmacotherapy, disease type, and region. The report also includes an in-depth regulatory analysis for various regions across the globe and competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global overactive bladder treatment market. The report analyzes the global overactive bladder treatment market by pharmacotherapy, disease type, and region.
• Product Innovation: Detailed insights on upcoming trends and new product launches in the global overactive bladder treatment market
• Market Development: Comprehensive information on the lucrative emerging markets by pharmacotherapy, disease type, and region
• Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the global overactive bladder treatment market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, products, and drugs in pipeline of leading players in the global market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVE OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED IN THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 ASSUMPTIONS

2 RESEARCH METHODOLOGY
2.1 RESEARCH METHODOLOGY STEPS
2.2 RESEARCH DESIGN
2.3 MARKET SIZE ESTIMATION
2.4 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ESTIMATION
2.3.1 KEY DATA POINTS TAKEN FROM SECONDARY SOURCES
2.3.2 KEY DATA POINTS TAKEN FROM PRIMARY SOURCES
2.3.2.1 Key Industry Insights

3 EXECUTIVE SUMMARY

4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 DEVELOPMENT OF INNOVATIVE INTRAVESICAL THERAPIES
4.2.2 AGGRESSIVE MARKETING BY PHARMA COMPANIES
4.2.3 AGING POPULATION AND RISING INCIDENCE OF DISEASES CHARACTERIZED BY OAB
4.3 RESTRAINTS
4.3.1 UNDESIRED SYSTEMIC EFFECTS OF CURRENT OAB TREATMENTS
4.4 OPPORTUNITIES
4.4.1 NOVEL TREATMENTS, ROBUST PIPELINE, AND PATENT CLIFF OF CERTAIN DRUGS
4.5 CHALLENGES
4.5.1 LACK OF AWARENESS ON OAB

5 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET,
BY PHARMACOTHERAPY
5.1 INTRODUCTION
5.2 ANTICHOLINERGICS
5.2.1 SOLIFENACIN
5.2.2 OXYBUTYNIN
5.2.3 FESOTERODINE
5.2.4 DARIFENACIN
5.2.5 TOLTERODINE
5.2.6 TROSPIUM
5.2.7 OTHER ANTICHOLINERGICS
5.3 MIRABEGRON
5.4 BOTOX
5.5 NEUROSTIMULATION
5.6 INTRAVESICAL INSTILLATION

6 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE
6.1 INTRODUCTION
6.2 IDIOPATHIC OVERACTIVE BLADDER
6.3 NEUROGENIC OVERACTIVE BLADDER
6.3.1 INTRODUCTION
6.3.2 OVERACTIVE BLADDER IN PARKINSON’S DISEASE
6.3.3 OVERACTIVE BLADDER IN STROKE
6.3.4 OVERACTIVE BLADDER IN MULTIPLE SCLEROSIS
6.3.5 OVERACTIVE BLADDER IN SPINAL CORD INJURY
6.3.6 OVERACTIVE BLADDER IN OTHER DISORDERS

7 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY REGION
7.1 INTRODUCTION
7.2 U.S.
7.2.1 FAVORABLE REIMBURSEMENT
7.2.2 STRONG PHARMA INDUSTRY AND SIGNIFICANT MARKETING EFFORTS
7.2.3 FAVORABLE DEMOGRAPHICS OF POPULATION AT RISK
7.2.4 INITIATIVES TO INCREASE AWARENESS ON OAB

7.3 EUROPE
7.3.1 INTRODUCTION
7.3.2 EU-5
7.3.2.1 Industry dynamics
7.3.2.2 Demographics and OAB prevalence
7.3.2.3 Attractive healthcare sector
7.3.2.4 Favorable reimbursement policies
7.3.2.5 Other factors
7.3.3 REST OF EUROPE
7.4 ASIA-PACIFIC
7.4.1 INTRODUCTION
7.4.2 JAPAN
7.4.3 REST OF ASIA-PACIFIC
7.5 REST OF THE WORLD (ROW)

8 MARKETED PRODUCTS
8.1 MARKETED PRODUCTS FOR OVERACTIVE BLADDER SYNDROME IN THE U.S.
8.2 MARKETED PRODUCTS FOR OVERACTIVE BLADDER SYNDROME IN EU-5

9 PIPELINE PRODUCTS
9.1 PIPELINE PRODUCTS FOR OVERACTIVE BLADDER SYNDROME IN THE U.S.
9.2 PIPELINE PRODUCTS FOR OVERACTIVE BLADDER SYNDROME IN EU-5

10 DRUG PROFILES
10.1 DARIFENACIN
10.2 FESOTERODINE
10.3 OXYBUTYNIN
10.4 SOLIFENACIN
10.5 TOLTERODINE
10.6 TROSPIUM
10.7 INJECTION BOTOX

11 COMPANY PROFILES
(Overview, Strength of Product Portfolio Business Strategy Excellence Products Offering, Recent Development’s, Business Strategy)*
11.1 ASTELLAS PHARMA INC.
11.2 PFIZER, INC.
11.3 TEVA PHARMACEUTICAL INDUSTRIES LIMITED
11.4 ALLERGAN, PLC.
11.5 MYLAN N.V.
11.6 ENDO INTERNATIONAL PLC
11.7 HISAMITSU PHARMACEUTICAL CO., INC.
11.8 SANOFI
11.9 AUROBINDO PHARMA LIMITED
11.10 JOHNSON & JOHNSON
11.11 INTAS PHARMACEUTICALS LTD.
11.12 APOTEX INC.
11.13 MACLEODS PHARMACEUTICALS LTD.
11.14 MEDTRONIC PLC
11.15 COGENTIX MEDICAL, INC.
*Details on Overview, Strength of Product Portfolio Business Strategy Excellence Products Offering, Recent Development’s, Business Strategy might not be captured in case of unlisted companies.

12 APPENDIX
12.1 INSIGHTS OF INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
12.5 AVAILABLE CUSTOMIZATIONS
12.6 RELATED REPORTS
12.7 AUTHORS DETAILS

LIST OF TABLES

TABLE 1 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY PHARMACOTHERAPY, 2015–2022 (USD MILLION)
TABLE 2 INDICATIVE LIST OF ANTICHOLINERGICS USED IN OAB TREATMENT
TABLE 3 GLOBAL ANTICHOLINERGICS MARKET FOR OVERACTIVE BLADDER TREATMENT, 2015–2022 (USD MILLION)
TABLE 4 GLOBAL ANTICHOLINERGICS MARKET FOR OVERACTIVE BLADDER TREATMENT,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 5 SOLIFENACIN MARKET FOR OVERACTIVE BLADDER TREATMENT,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 6 OXYBUTYNIN MARKET FOR OVERACTIVE BLADDER TREATMENT,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 7 FESOTERODINE MARKET FOR OVERACTIVE BLADDER TREATMENT,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 8 DARIFENACIN MARKET FOR OVERACTIVE BLADDER TREATMENT,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 9 TOLTERODINE MARKET FOR OVERACTIVE BLADDER TREATMENT,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 10 TROSPIUM MARKET FOR OVERACTIVE BLADDER TREATMENT,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 11 OTHER ANTICHOLINERGICS MARKET FOR OVERACTIVE BLADDER TREATMENT,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 12 MIRABEGRON MARKET FOR OVERACTIVE BLADDER TREATMENT,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 13 BOTOX MARKET FOR OVERACTIVE BLADDER TREATMENT, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 14 NEUROSTIMULATION MARKET FOR OVERACTIVE BLADDER TREATMENT,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 15 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION)
TABLE 16 GLOBAL IDIOPATHIC OVERACTIVE BLADDER TREATMENT MARKET,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 17 GLOBAL NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE, 2015–2022 (USD MILLION)
TABLE 18 GLOBAL NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 19 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET FOR PARKINSON’S DISEASE, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 20 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET FOR STROKE,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 21 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 22 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET FOR SPINAL CORD INJURIES, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 23 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER DISORDERS,
BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 24 OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY/REGION,
2015–2022 (USD MILLION)
TABLE 25 U.S.: OVERACTIVE BLADDER TREATMENT MARKET, BY PHARMACOTHERAPY, 2015–2022 (USD MILLION)
TABLE 26 U.S. OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION)
TABLE 27 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
TABLE 28 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY PHARMACOTHERAPY, 2015–2022 (USD MILLION)
TABLE 29 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION)
TABLE 30 EU-5: OVERACTIVE BLADDER TREATMENT MARKET, BY PHARMACOTHERAPY, 2015–2022 (USD MILLION)
TABLE 31 EU-5: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION)
TABLE 32 ROE: OVERACTIVE BLADDER TREATMENT MARKET, BY PHARMACOTHERAPY, 2015–2022 (USD MILLION)
TABLE 33 ROE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION)
TABLE 34 APAC: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY/REGION,
2015–2022 (USD MILLION)
TABLE 35 APAC: OVERACTIVE BLADDER TREATMENT MARKET, BY PHARMACOTHERAPY, 2015–2022 (USD MILLION)
TABLE 36 APAC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION)
TABLE 37 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY PHARMACOTHERAPY, 2015–2022 (USD MILLION)
TABLE 38 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION)
TABLE 39 ROAPAC: OVERACTIVE BLADDER TREATMENT MARKET, BY PHARMACOTHERAPY, 2015–2022 (USD MILLION)
TABLE 40 ROAPAC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION)
TABLE 41 ROW: OVERACTIVE BLADDER TREATMENT MARKET, BY PHARMACOTHERAPY, 2015–2022 (USD MILLION)
TABLE 42 ROW: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION)
TABLE 43 U.S.: MARKETED PRODUCTS IN OVERACTIVE BLADDER TREATMENT MARKET
TABLE 44 EU-5: MARKETED PRODUCTS IN OVERACTIVE BLADDER TREATMENT MARKET
TABLE 45 U.S.: PIPELINE PRODUCTS IN OVERACTIVE BLADDER TREATMENT MARKET
TABLE 46 EU-5: PIPELINE PRODUCTS IN OVERACTIVE BLADDER TREATMENT MARKET
TABLE 47 DRUG PROFILE: DARIFENACIN
TABLE 48 DRUG PROFILE: FESOTERODINE
TABLE 49 DRUG PROFILE: OXYBUTYNIN
TABLE 50 DRUG PROFILE: SOLIFENACIN
TABLE 51 DRUG PROFILE: TOLTERODINE
TABLE 52 DRUG PROFILE: TROSPIUM
TABLE 53 DRUG PROFILE: BOTOX (ONABOTULINUMTOXINA)


LIST OF FIGURES

FIGURE 1 OVERACTIVE BLADDER TREATMENT MARKET
FIGURE 2 YEARS CONSIDERED FOR STUDY – 2017: ESTIMATED YEAR, 2022:
PROJECTED YEAR
FIGURE 3 RESEARCH METHODOLOGY: SECONDARY RESEARCH, PRIMARY RESEARCH,
AND MARKET BREAKDOWN STEPS
FIGURE 4 RESEARCH DESIGN
FIGURE 5 SECONDARY RESEARCH
FIGURE 6 MARKET SIZE (USD) ESTIMATION METHODOLOGY
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
FIGURE 9 OVERACTIVE BLADDER TREATMENT: MARKET OVERVIEW (USD BILLION)
FIGURE 10 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY PHARMACOTHERAPY (USD MILLION)
FIGURE 11 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET,
BY DISEASE TYPE (USD MILLION)
FIGURE 12 GLOBAL NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY DISEASES (USD MILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE OVERACTIVE BLADDER TREATMENT MARKET
FIGURE 14 OVERACTIVE BLADDER TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNIITIES, AND CHALLENGES
FIGURE 15 GERIATRIC POPULATION (AGED 60 AND ABOVE) PERCENTAGE IN 2015 & 2030
FIGURE 16 OVERACTIVE BLADDER TREATMENT MARKET SEGMENTATION
BY PHARMACOTHERAPY
FIGURE 17 OVERACTIVE BLADDER DIAGNOSIS AND TREATMENT
FIGURE 18 OVERACTIVE BLADDER TREATMENT MARKET SEGMENTATION BY DISEASE TYPE
FIGURE 19 ESTIMATED OAB PREVALENCE IN THE U.S. AND EU-5 (2015)
FIGURE 20 PREVALENCE OF MS PER 100,000 INDIVIDUALS
FIGURE 21 OVERACTIVE BLADDER TREATMENT MARKET IN ROAPAC TO GROW AT THE HIGHEST RATE (2017–2022)
FIGURE 22 U.S.: BRANDED VS. GENERIC PRESCRIPTION DRUG REVENUES (2011-2016)
FIGURE 23 U.S.: ELDERLY POPULATION (AGED 65 YEARS AND ABOVE)
FIGURE 24 U.S.: OBESE POPULATION (BMI ≥ 30)
FIGURE 25 U.S.: NATIONAL HEALTH EXPENDITURE AS % OF GDP
FIGURE 26 GERMANY HEALTHCARE EXPENDITURE AS A % OF GDP
FIGURE 27 ITALY: PUBLIC AND PRIVATE HEALTHCARE SPENDING
FIGURE 28 ASTELLAS PHARMA, INC.: COMPANY SNAPSHOT (2016)
FIGURE 29 PFIZER, INC.: COMPANY SNAPSHOT (2016)
FIGURE 30 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT (2016)
FIGURE 31 ALLERGAN, PLC: COMPANY SNAPSHOT (2016)
FIGURE 32 MYLAN N.V.: COMPANY SNAPSHOT (2016)
FIGURE 33 ENDO INTERNATIONAL PLC: COMPANY SNAPSHOT (2016)
FIGURE 34 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2015)
FIGURE 35 SANOFI: COMPANY SNAPSHOT (2016)
FIGURE 36 AUROBINDO PHARMA LIMITED: COMPANY SNAPSHOT (2015)
FIGURE 37 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2016)
FIGURE 38 MEDTRONIC PLC: COMPANY SNAPSHOT (2016)
FIGURE 39 COGENTIX MEDICAL, INC.: COMPANY SNAPSHOT (2016)


【レポートのキーワード】

過活動膀胱、過活動膀胱治療、抗コリン・ソリフェナシン、オキシブチニン、フェソテロジン、ダリフェナシン、ミラベグロン、ボトックス、神経刺激、医薬品

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[過活動膀胱(OAB)治療の世界市場予測(~2022年):抗コリン・ソリフェナシン、オキシブチニン、フェソテロジン、ダリフェナシン、ミラベグロン、ボトックス、神経刺激]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチのお客様(例)◆